| Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. | |
| | |
MedLine Citation:
|
PMID: 19237175 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Tumor associated macrophages can regulate the growth of various cancers positively or negatively. Intravesical bacillus Calmette-Guerin instillation is now gold standard treatment for bladder carcinoma in situ. We investigated the correlation between tumor associated macrophages infiltrating bladder carcinoma in situ and the response to intravesical bacillus Calmette-Guerin therapy. MATERIALS AND METHODS: We examined paraffin embedded tissues from 41 patients with bladder carcinoma in situ who received intravesical bacillus Calmette-Guerin therapy. Tumor associated macrophages were immunohistochemically stained by anti-CD68 monoclonal antibody. RESULTS: The median number of tumor associated macrophages infiltrating among cancer cells and the number in the lamina propria were 4 and 24, respectively. Recurrent carcinoma in situ was found in 4.8% of cases with a lower cancer cell tumor associated macrophage count but in 47.6% of those with a higher cancer cell tumor associated macrophage count (less than 4 vs 4 or greater). Recurrence was found in 31.8% of patients with a lower lamina propria tumor associated macrophage count but in 21.1% of those with a higher lamina propria tumor associated macrophage count (less than 25 vs 25 or greater). The median ratio of tumor associated macrophages among cancer cells vs in the lamina propria was 0.2. Recurrence-free survival was significantly better in patients with a lower cancer cell tumor associated macrophage count (p = 0.0002). Those with a lower cancer cell-to-lamina propria tumor associated macrophage ratio had a higher recurrence-free rate (p <0.0001). Multivariate analysis revealed that the cancer cell tumor associated macrophage count and the cancer cell-to-lamina propria tumor associated macrophage ratio can be prognostic factors for bladder carcinoma in situ. CONCLUSIONS: The count of tumor associated macrophages infiltrating the cancer area is useful for predicting the response of bladder carcinoma in situ to intravesical bacillus Calmette-Guerin instillation before treatment initiation. |
| | |
Authors:
|
Hitoshi Takayama; Kazuo Nishimura; Akira Tsujimura; Yasutomo Nakai; Masashi Nakayama; Katsuyuki Aozasa; Akihiko Okuyama; Norio Nonomura |
Related Documents
:
|
15021975 - Upregulation of bronchioloalveolar carcinoma-derived c-x-c chemokines by tumor infiltra... 21958215 - Adaptation to survival in germinal center is the initial step in onset of indolent stag... 2950265 - Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice. 22300755 - Detailed biopsy pathologic features as predictive factors for initial reclassification ... 10453725 - Characterization of mgi 114 (hmaf) histiospecific toxicity in human tumor cell lines. 7233655 - Usefulness of preoperative transcatheter embolization in kidney tumors. |
Publication Detail:
|
Type: Journal Article Date: 2009-02-23 |
Journal Detail:
|
Title: The Journal of urology Volume: 181 ISSN: 1527-3792 ISO Abbreviation: J. Urol. Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-03-19 Completed Date: 2009-04-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0376374 Medline TA: J Urol Country: United States |
Other Details:
|
Languages: eng Pagination: 1894-900 Citation Subset: AIM; IM |
Affiliation:
|
Departments of Urology and Pathology (KA), Osaka University Graduate School of Medicine, Suita, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
administration & dosage* Administration, Intravesical Aged Aged, 80 and over BCG Vaccine / administration & dosage* Carcinoma in Situ / pathology* Cell Movement Female Humans Macrophages / pathology* Male Middle Aged Prognosis Urinary Bladder Neoplasms / pathology* |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/BCG Vaccine |
| Comments/Corrections | |
Comment In:
|
J Urol. 2009 Apr;181(4):1532-3
[PMID:
19230928
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mechanisms of action of eicosapentaenoic acid in bladder cancer cells in vitro: alterations in mitoc...
Next Document: Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium...